Navigation Links
WHO guidelines on Buruli ulcer need adjustment
Date:6/18/2010

Buruli ulcers, one of the 'neglected tropical diseases' left aside by big pharma and governments alike, are reasonably well treatable, also in poor regions. But then more attention has to be paid to early diagnosis and correct treatment. This means the rules of the World Health Organization urgently need to be changed. So say scientists of the Antwerp Institute of Tropical Medicine (ITM), based on ten years of research in Congo.

The disease is caused by Mycobacterium ulcerans, a nephew of the infamous tuberculosis bacterium. It occurs in tropical and subtropical countries, mainly in Africa. It causes hideously ulcerating 'holes' in the skin, that can dig to the bone and can outgrow to diameters of more than 10 centimetres. Much about the disease is unknown, for instance how exactly people get infected. It is assumed that water plays a role, but only in 2008 scientists at ITM succeeded in cultivating the bacterium from a water insect.

For a long time the only treatment consisted of caring for the wounds, and possibly a skin transplantation. Nowadays the WHO proposes a treatment analogous to tuberculosis, with two antibiotics, rifampicin and streptomycin. This works for light cases, but for lesions above 10 cm the effect was not documented. ITM scientist Anatole Kibadi Kapay collected cases in DR Congo from the previous five years, when surgery combined with antibiotics was used, and from the five year before that, when only surgery was used. In the process he discovered a new focus close to the Angolan border; he assumes it to be correlated to the working conditions in the illegal diamond mines there.

Kibadi Kapay noticed that the WHO guidelines for clinical diagnosis lead to a correct diagnosis in only 2 cases out of 3. As opposed to a Ziehl-Neelsen smear, a microscopic technique that is within reach of poor countries and that, through a better diagnosis, prevents the needless use of antibiotics.

But when large wounds have to be treated, from a microscopically confirmed Buruli case, antibiotics indeed are of good use. With surgery only, 15% of patients relapse; with parallel use of antibiotics, less than 2% relapse. But antibiotics only, without surgery, make large wounds worse.

Kibadi Kapay who today received a doctorate from Antwerp University for his work and his ITM colleagues advocate faster surgery of large ulcerating lesions, without four weeks of waiting with antibiotics only. The more because patients themselves already wait a long time before consulting a doctor to them the ulcers are inflicted by witchcraft or fate.

The research by Kibadi Kapay demonstrates the need of a better education of the population, but more important, it shows that WHO guidelines for diagnosis and treatment of Buruli ulcers urgently need to be adapted.


'/>"/>

Contact: Anatole Kibadi Kapay
akibadi@yahoo.fr
32-485-477-564
Institute for Tropical Medicine Antwerp
Source:Eurekalert

Related biology news :

1. UNC study questions FDA genetic-screening guidelines for cancer drug
2. 2 carotid artery stenting studies show results comparable to AHA guidelines
3. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
4. NHLBI issues first US von Willebrand Disease clinical practice guidelines
5. New guidelines for treating rheumatoid arthritis
6. Study finds ATV guidelines inadequate
7. Guidelines urge physical activity during pregnancy
8. The International Society for Stem Cell Research releases new guidelines
9. Publication sets guidelines across cancer therapies: Ensuring the best in patient management
10. Coral Disease Handbook: Guidelines for Assessment, Monitoring and Management
11. First comprehensive guidelines for managing medullary thyroid carcinoma published in Thyroid journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
(Date:2/23/2017)... 2017 Aviva Systems Biology Corporation (ASB) ... of GenWay Biotech Incorporated, a protein solutions and ... offering for both the research and diagnostic markets. ... enhance capabilities for both entities. GenWay,s 18 years of ... nicely complement ASB,s objective to become a leading ...
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: ... and commercialization of innovative biopharmaceutical products for companion animals, will ... at 8:30 a.m. ET to discuss financial results from the ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017  PrimeVax ... , will be presenting at the Annual Biocom Global ... on March 2, at 11:15 AM, at the Torrey ... are thankful to the organizers at Biocom who have ... this international symposium of biotechnology companies, investors, and clinical ...
Breaking Biology Technology: